通过趋化因子CXCL9的PET成像监测肿瘤微环境中t细胞的活化

Orit Jacobson, Hongwei H. Zhang, Colleen P. Olkowski, Behnaz Ghaemi, Falguni Basuli, Jianfeng Shi, Meghan M. Bell, Farhat Parween, Sundar Ganesan, Thomas J. Esparza, Freddy E. Escorcia, Peter L. Choyke, Joshua M. Farber
{"title":"通过趋化因子CXCL9的PET成像监测肿瘤微环境中t细胞的活化","authors":"Orit Jacobson, Hongwei H. Zhang, Colleen P. Olkowski, Behnaz Ghaemi, Falguni Basuli, Jianfeng Shi, Meghan M. Bell, Farhat Parween, Sundar Ganesan, Thomas J. Esparza, Freddy E. Escorcia, Peter L. Choyke, Joshua M. Farber","doi":"10.2967/jnumed.125.269795","DOIUrl":null,"url":null,"abstract":"<p>Noninvasive monitoring of immune responses is important for increasing the efficacy of cancer immunotherapy. Although several approaches exist, few methods directly report on T-cell activation. We aimed to develop a novel PET probe targeting C-X-C motif chemokine ligand 9 (CXCL9), a chemokine specifically induced by interferon gamma (IFN-γ), a cytokine that is produced by activated T cells and group 1 innate lymphoid cells. CXCL9 binds to glycosaminoglycans, which are expressed on cell surfaces and the extracellular matrix, to recruit or position cells in the tumor microenvironment. In cancers, expression of CXCL9 has been associated with improved survival and predicts and reflects responses to immunotherapy. The pronounced upregulation of CXCL9 by IFN-γ and CXCL9’s extracellular accessibility and site-specific accumulation make it a compelling biomarker for detecting T-cell activation. <strong>Methods:</strong> We developed a PET tracer targeting CXCL9 based on a high-affinity, antihuman CXCL9 nanobody (h2A12), which was isolated from a llama-derived phage display library and labeled with <sup>18</sup>F. The tracer was evaluated in cell culture, a subcutaneous xenograft model, and a humanized mouse model of T-cell engager therapy. <strong>Results:</strong> The h2A12 nanobody demonstrated high specificity for human CXCL9 (<em>K</em><sub>d</sub>, 4.07 ± 0.44 nM) with no cross-reactivity to related chemokines. In xenograft models, [<sup>18</sup>F]F-h2A12 showed significant uptake in CXCL9-expressing tumors (10.33 ± 1.23 %IA/g) compared with control tumors (0.25 ± 0.04 %IA/g) at 2 h after injection, with excellent tumor-to-background ratios. In the humanized model, T-cell engager therapy induced CXCL9 expression that peaked at day 7, corresponding with increased [<sup>18</sup>F]F-h2A12 uptake in treated tumors (2.61 ± 0.50 %IA/g) versus controls (0.67 ± 0.12 %IA/g). <strong>Conclusion:</strong> [<sup>18</sup>F]F-h2A12 PET imaging enables noninvasive visualization of CXCL9 expression as a biomarker of immune activation. This approach offers potential applications in monitoring immunotherapy responses and studying immune-mediated diseases.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Monitoring T-Cell Activation in the Tumor Microenvironment by PET Imaging of the Chemokine CXCL9\",\"authors\":\"Orit Jacobson, Hongwei H. Zhang, Colleen P. Olkowski, Behnaz Ghaemi, Falguni Basuli, Jianfeng Shi, Meghan M. Bell, Farhat Parween, Sundar Ganesan, Thomas J. Esparza, Freddy E. Escorcia, Peter L. Choyke, Joshua M. Farber\",\"doi\":\"10.2967/jnumed.125.269795\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Noninvasive monitoring of immune responses is important for increasing the efficacy of cancer immunotherapy. Although several approaches exist, few methods directly report on T-cell activation. We aimed to develop a novel PET probe targeting C-X-C motif chemokine ligand 9 (CXCL9), a chemokine specifically induced by interferon gamma (IFN-γ), a cytokine that is produced by activated T cells and group 1 innate lymphoid cells. CXCL9 binds to glycosaminoglycans, which are expressed on cell surfaces and the extracellular matrix, to recruit or position cells in the tumor microenvironment. In cancers, expression of CXCL9 has been associated with improved survival and predicts and reflects responses to immunotherapy. The pronounced upregulation of CXCL9 by IFN-γ and CXCL9’s extracellular accessibility and site-specific accumulation make it a compelling biomarker for detecting T-cell activation. <strong>Methods:</strong> We developed a PET tracer targeting CXCL9 based on a high-affinity, antihuman CXCL9 nanobody (h2A12), which was isolated from a llama-derived phage display library and labeled with <sup>18</sup>F. The tracer was evaluated in cell culture, a subcutaneous xenograft model, and a humanized mouse model of T-cell engager therapy. <strong>Results:</strong> The h2A12 nanobody demonstrated high specificity for human CXCL9 (<em>K</em><sub>d</sub>, 4.07 ± 0.44 nM) with no cross-reactivity to related chemokines. In xenograft models, [<sup>18</sup>F]F-h2A12 showed significant uptake in CXCL9-expressing tumors (10.33 ± 1.23 %IA/g) compared with control tumors (0.25 ± 0.04 %IA/g) at 2 h after injection, with excellent tumor-to-background ratios. In the humanized model, T-cell engager therapy induced CXCL9 expression that peaked at day 7, corresponding with increased [<sup>18</sup>F]F-h2A12 uptake in treated tumors (2.61 ± 0.50 %IA/g) versus controls (0.67 ± 0.12 %IA/g). <strong>Conclusion:</strong> [<sup>18</sup>F]F-h2A12 PET imaging enables noninvasive visualization of CXCL9 expression as a biomarker of immune activation. This approach offers potential applications in monitoring immunotherapy responses and studying immune-mediated diseases.</p>\",\"PeriodicalId\":22820,\"journal\":{\"name\":\"The Journal of Nuclear Medicine\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Nuclear Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2967/jnumed.125.269795\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Nuclear Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnumed.125.269795","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

无创监测免疫反应对提高癌症免疫治疗的疗效非常重要。虽然有几种方法存在,但很少有方法直接报道t细胞的活化。我们旨在开发一种针对C-X-C基序趋化因子配体9 (CXCL9)的新型PET探针,CXCL9是一种由干扰素γ (IFN-γ)特异性诱导的趋化因子,干扰素γ是一种由活化的T细胞和1组先天淋巴样细胞产生的细胞因子。CXCL9结合在细胞表面和细胞外基质上表达的糖胺聚糖,在肿瘤微环境中招募或定位细胞。在癌症中,CXCL9的表达与生存率的提高有关,并预测和反映对免疫治疗的反应。IFN-γ对CXCL9的显著上调以及CXCL9的细胞外可及性和位点特异性积累使其成为检测t细胞活化的一个令人信服的生物标志物。方法:基于高亲和力的抗人CXCL9纳米体(h2A12),我们开发了一种靶向CXCL9的PET示踪剂,该纳米体是从羊源噬菌体展示文库中分离出来的,用18F标记。该示踪剂在细胞培养、皮下异种移植模型和t细胞接合治疗的人源化小鼠模型中进行了评估。结果:h2A12纳米体对人CXCL9具有较高的特异性(Kd, 4.07±0.44 nM),与相关趋化因子无交叉反应性。在异种移植瘤模型中,[18F]F-h2A12在注射后2小时在表达cxcl9的肿瘤中明显摄取(10.33±1.23% IA/g),而对照肿瘤(0.25±0.04 %IA/g),具有良好的肿瘤-背景比。在人源化模型中,t细胞接合剂治疗诱导CXCL9表达在第7天达到峰值,与治疗肿瘤中[18F]F-h2A12摄取增加(2.61±0.50% IA/g)相对应,对照组(0.67±0.12% IA/g)。结论:[18F]F-h2A12 PET成像可以无创地显示CXCL9的表达,作为免疫激活的生物标志物。这种方法在监测免疫治疗反应和研究免疫介导疾病方面具有潜在的应用前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Monitoring T-Cell Activation in the Tumor Microenvironment by PET Imaging of the Chemokine CXCL9

Noninvasive monitoring of immune responses is important for increasing the efficacy of cancer immunotherapy. Although several approaches exist, few methods directly report on T-cell activation. We aimed to develop a novel PET probe targeting C-X-C motif chemokine ligand 9 (CXCL9), a chemokine specifically induced by interferon gamma (IFN-γ), a cytokine that is produced by activated T cells and group 1 innate lymphoid cells. CXCL9 binds to glycosaminoglycans, which are expressed on cell surfaces and the extracellular matrix, to recruit or position cells in the tumor microenvironment. In cancers, expression of CXCL9 has been associated with improved survival and predicts and reflects responses to immunotherapy. The pronounced upregulation of CXCL9 by IFN-γ and CXCL9’s extracellular accessibility and site-specific accumulation make it a compelling biomarker for detecting T-cell activation. Methods: We developed a PET tracer targeting CXCL9 based on a high-affinity, antihuman CXCL9 nanobody (h2A12), which was isolated from a llama-derived phage display library and labeled with 18F. The tracer was evaluated in cell culture, a subcutaneous xenograft model, and a humanized mouse model of T-cell engager therapy. Results: The h2A12 nanobody demonstrated high specificity for human CXCL9 (Kd, 4.07 ± 0.44 nM) with no cross-reactivity to related chemokines. In xenograft models, [18F]F-h2A12 showed significant uptake in CXCL9-expressing tumors (10.33 ± 1.23 %IA/g) compared with control tumors (0.25 ± 0.04 %IA/g) at 2 h after injection, with excellent tumor-to-background ratios. In the humanized model, T-cell engager therapy induced CXCL9 expression that peaked at day 7, corresponding with increased [18F]F-h2A12 uptake in treated tumors (2.61 ± 0.50 %IA/g) versus controls (0.67 ± 0.12 %IA/g). Conclusion: [18F]F-h2A12 PET imaging enables noninvasive visualization of CXCL9 expression as a biomarker of immune activation. This approach offers potential applications in monitoring immunotherapy responses and studying immune-mediated diseases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信